SEARCH

SEARCH BY CITATION

References

  • 1
    Hoofhagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggener JG, et al. Treatment of chronic non-A non-B hepatitis with reconibinant human alpha interferon: a niulticenter randomized, controlled trial. N Engl J Med 1986; 315: 15751578.
  • 2
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr., Perrillo RP, Galey W, et al. Treatment of chronic hepatitis C with reconibinant interferon alpha: niulticenter randomized, controlled trial. N Engl J Med 1989; 321: 15011506.
  • 3
    Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, Kobayashi M, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991; 13: 10401043.
  • 4
    Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992; 15: 10131016.
  • 5
    Yamamoto M, Uemura T, Nakama S, Uemiya M, Kasayama S, Kishida Y, Yamauchi K, et al. A fundamental study of chronic hepatitis treated with saiko agents. Proceedings of the Symposium of Wakan-Yaku 1983; 16: 245248.
  • 6
    Oka H, Fujiwara K, Oda T. Xiano-Chai-Hu-Tang and Gui-Zhi-Fu-Ling-Wan for treatment of chronic hepatitis. In: OdaT, NeedhamJ, OtsukaY, Guo-binL, eds. Recent Advances in Traditional Medicine in the East Asia. Amsterdam: Excerpta Medica, 1984: 232237.
  • 7
    Fujiwara K, Ohta Y, Ogata I, Hayashi S, Sato Y, Oka Y, Yamada S, et al. Treatment trial of traditional Oriental medicine in chronic viral hepatitis. In: OtaY, ed. New Trends in Peptic Ulcer and Chronic Hepatitis: Part II. Chronic Hepatitis. Tokyo: Excerpta Medica, 1987: 141146.
  • 8
    Tajiri H, Kozaiwa K, Osaki Y, Hamamoto T, Miki K, Shimizu K, Ida S, et al. The study of the effect of Sho-saiko-to on HBeAg clearance in children with chronic HBV infection and with abnormal liver function test results. Acta Paediatr Jpn 1990; 94: 18111815.
  • 9
    Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, Monna T, et al. Prospective study of chemotherapy of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995; 76: 743749.
  • 10
    Yano H, Mizoguchi A, Fukuda K, Haramaki M, Ogasawara S, Momosaki S, Kojiro M. The herbal medicine Sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the GO/G1 phase. Cancer Res 1994; 54: 448454.
  • 11
    Ikemoto Y, Mizoguchi Y, Arai T, Yamamoto S, Morisawa S. Effect of Sho-saiko-to and Dai-saiko-to on in vitro antibody production. Wakan Pharmaceutical Society Journal 1984; 1: 235242.
  • 12
    Mizoguchi Y, Fujinobu Y, Kobayashi K, Yamamoto S, Morisawa S. Effects of Sho-saiko-to on natural killer (NK) cell activity. Wakan Pharmaceutical Society Journal 1986; 3: 184189.
  • 13
    Mizoguchi Y, Sakagami Y, Higashimori T, Monna T. Preventive effects of saikosaponins in immunological hepatic cell injury. Acta Hepatol Jpn 1984; 25: 4045.
  • 14
    Fujiwara K, Ogihara Y. Pharmacological effect of oral saikosaponin may differ depending on conditions of the gastrointestinal tract. Life Sci 1986; 4: 297301.
  • 15
    Amagaya S, Hayakawa M, Ogihara Y, Ohta Y, Fujiwara K, Oka H, Oshio H, Kishi T. Treatment of chronic liver injury in mice by oral administration of Xiao-Chai-Hu-Tang. J Ethnopharmacol 1989; 25: 181187.
  • 16
    Mizoguchi Y, Kawada N, Ichikawa Y, Yamamoto S. Effect of Sho-saiko-to on interleukin-1 production by hepatic sinusoidal endothelial cells. Wakan Pharmaceutical Society Journal 1989; 6: 172176.
  • 17
    Kakumu S, Yoshioka K, Wakita T, Ishikawa T. Effect of TJ-9, Sho-saiko-to (a Kampo Medicine), on interferon-y and antibody productions specific to hepatitis B virus in patients with type B chronic hepatitis. Int J Immunopharmac 1990; 13: 141146.
  • 18
    Yamashiki M, Asakawa M, Kayaba Y, Kosaka Y, Nishimura A. Herbal medicine “Sho-saiko-to” induces in vitro granulocyte colony-stimulating factor production on peripheral blood mononuclear cells. J Clin Lab Immunol 1992; 37: 8390.
  • 19
    Yamashiki M, Kosaka Y, Nishimura A, Hamaguchi K, Okuda Y, Ichida F. The herbal medicine “Sho-saiko-to” improves cytokine production of peripheral blood mononuclear cells in patients with liver cirrhosis. Curr Ther Res 1993; 54: 8697.
  • 20
    Yamashiki M, Nishimura A, Kosaka Y. Effect of the herbal medicine “Sho-saiko-to” (TJ-9) on in vitro TNF-a and G-CSF production capability of peripheral blood mononuclear cells from liver cancer and liver cirrhosis patients. Hepatology 1993; 18 (suppl): 323A.
  • 21
    Yamashiki M, Nishimura A, Nomoto M, Suzuki H, Nakano T, Sato T, James SP, et al. Effect of Japanese herbal medicine “Sho-saiko-to” on in vitro production of tumor necrosis factor-alpha on peripheral blood mono-nuclear cells. Drug Develop Res 1994; 31: 170174.
  • 22
    Yamashiki M, Nishimura A, Nomoto M, Suzuki H, Kosaka Y. Herbal medicine “Sho-saiko-to” induces tumor necrosis factor-a and granulocyte colony-stimulating factor in vitro in peripheral blood mononuclear cells of patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1996; 11: 137142.
  • 23
    Florentine DF, Bond MW, Mosmann TR. Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J Exp Med 1989; 170: 20812095.
  • 24
    Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mossman TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Ep-stein-Barr virus gene BCRF1. Science 1990; 248: 12301234.
  • 25
    Vieira P, de Waal-Malefyt R, Dang M-N, Johnson KE, Kastelein R, Fiorentino DF, DeVries JE, et al. Isolation and expression of human cytokine synthesis inhibitory factor (CSIF/IL-10) cDNA clones: homology to Ep-stein-Barr virus open reading frame BCRF1. Proc Natl Acad Sci USA 1991; 88: 11721176.
  • 26
    Ishida H, Hastings R, Kearney J, Howard M. Continuous anti-interleukin 10 antibody administration depletes Ly-1 B cells but not conventional B cells. J Exp Med 1992; 175: 12131220.
  • 27
    Ishida H, Hastings R, Snipes L, Haward M. Modified immunological status of anti-ILlO treated mice. Cell Immunol 1993; 148: 371384.
  • 28
    Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263274.
  • 29
    Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 12051208.
  • 30
    Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-IL-10 antibodies delays onset of auto immunity in NZB/W Fl mice. J Exp Med 1994; 179: 305310.
  • 31
    Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71: 169175.
  • 32
    Moritani M, Yoshimoto K, Tashiro F. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol 1994; 6: 19271930.
  • 33
    Tanaka M, Nagaki M, Noda N, Sugiyama A, Ohnishi H, Moriwaki H, Muto T. [Titled in Japanese]. Jpn J Gastroenterol 1995; 92 (suppl): 1474.